From the publishers of JADPRO

Metastatic HER2-Positive Breast Cancer Resource Center


Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis

Last Updated: Tuesday, April 11, 2023

Pyrotinib-containing regimens demonstrate tumor response, disease control, and survival with manageable toxicity in any line of treatment for HER2-positive metastatic breast cancer, according to data from a systematic review and meta-analysis of prospective and retrospective trials. Overall objective response rate was 0.49 (95% CI: 0.40-0.58) and 0.52 (95% CI: 0.32-0.71) in a subgroup of patients with brain metastases, and combined median PFSs were 8.2 months (95% CI: 6.8-9.5) and 8.9 months (95% CI: 6.2-11.7) for the brain metastases group.

Translational Cancer Research
News & Literature Highlights

Nature Reviews Drug Discovery

Targeting HER2-positive breast cancer: advances and future directions

ESMO Congress 2022 Abstract

Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

ESMO Congress 2022 Abstract

Clinical safety and pharmacokinetics (PK) data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer

ESMO Congress 2022 Abstract

Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan

Cancer Network

Early efficacy observed with trastuzumab deruxtecan ± pertuzumab for HER2+ metastatic breast cancer

Oncology Nursing News

DESTINY-Breast02 confirms benefit of trastuzumab deruxtecan in previously treated patients with HER2+ metastatic breast cancer

Targeted Oncology

Safety of tucatinib triplet for HER2+ breast cancer sealed in real-world analysis

The ASCO Post

T-DXd confirmed as preferred second-line therapy for metastatic HER2-positive breast cancer

Clinical Breast Cancer

A phase II single-arm study of palbociclib in patients with HER2-positive breast cancer with brain metastases and analysis of ctDNA in patients with active brain metastases

Frontiers in Oncology

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review